Results 21 to 30 of about 77,174 (152)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells

, 2021
Resistance to temozolomide and intratumoral heterogeneity contribute to the poor prognosis of glioma. The mechanisms of temozolomide resistance can vary within a heterogeneous tumor. Temozolomide adds a methyl group to DNA.
Yuichi Hirose, Shigeo Ohba, Kei Yamashiro   +2 more
core   +1 more source

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

ESMO Open, 2020
Background Most glioblastoma tumours exhibit intrinsic phosphatidylinositol 3-kinase (PI3K) pathway activation. Preclinical in vitro and in vivo models suggest that buparlisib (an oral pan-PI3K inhibitor) can have an effect on glioblastoma directly and ...
David Mills, Patrick Yung Wen, Jordi A Rodon, Warren Mason, Joseph T Beck, John DeGroot, Valerie Donnet, Mona El-Hashimy, Mark Rosenthal   +8 more
doaj   +1 more source

Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report

Journal of Medical Case Reports, 2010
Introduction We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be ...
Shaikh Asim, Masood Nehal
doaj   +1 more source

Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma [PDF]

, 2013
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system.
Abramson, Jeremy S, Clark, Stephen W, Taylor, Jennie, Wang, Daphne L, Batchelor, Tracy T   +4 more
core   +1 more source

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888.
Plummer ER, Grogan PT, Clarke MJ, Curtin NJ, Carlson BL, Mulligan EA, Schroeder MA, Decker PA, Wu W, Sarkaria JN, Mladek AC, Lou Z   +11 more
core   +4 more sources

Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles [PDF]

, 2011
Xin-Hua Tian1, Xiao-Ning Lin1, Feng Wei1, Wei Feng1, Zhi-Chun Huang1, Peng Wang1, Lei Ren2, Yi Diao11Department of Neurosurgery, Zhongshan Hospital of Xiamen University, Xiamen, People's Republic of China; 2Research Center of Biomedical ...
Tian, Xin-Hua, Wang, Peng, Diao, Yi, 任磊, null Wei, null Ren, Huang, Zhi-Chun, Wei, Feng, Ren, Lei, null Huang, Feng Wei, Xin-Hua Tian, null Diao, null Feng, Lin, Xiao-Ning, null Tian, null Wang, Feng, Wei, et al, Xiao-Ning Lin   +19 more
core   +1 more source

Metabolic activation of temozolomide measured in vivo using positron emission tomography

, 2003
The purpose of this research was to quantitate and confirm the mechanism of in vivo metabolic activation of temozolomide. The secondary aims were to evaluate the tumor, normal tissue, and plasma pharmacokinetics of temozolomide in vivo, and to determine ...
Stevens, Malcolm F G, Price, Pat, Ranicar, Alex S O, Newlands, Edward, Brown, Gavin D., Aboagye, Eric O., Brock, Cathryn S., Brady, Frank, Luthra, Sajinder K., Saleem, Azeem, Jones, Terry, Osman, Safiye   +11 more
core   +6 more sources

Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.

PLoS ONE, 2019
Glioblastoma is the leading malignant glioma with a poor prognosis. This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma.
Yoshitaka Tanaka, Tsutomu Nakazawa, Mitsutoshi Nakamura, Fumihiko Nishimura, Ryosuke Matsuda, Koji Omoto, Yoichi Shida, Toshiharu Murakami, Ichiro Nakagawa, Yasushi Motoyama, Hiromichi Morita, Takahiro Tsujimura, Hiroyuki Nakase   +12 more
doaj   +1 more source

The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

Fluids and Barriers of the CNS, 2018
Background The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug ...
Sadhana Jackson, Jon Weingart, Edjah K. Nduom, Thura T. Harfi, Richard T. George, Dorothea McAreavey, Xiaobu Ye, Nicole M. Anders, Cody Peer, William D. Figg, Mark Gilbert, Michelle A. Rudek, Stuart A. Grossman   +12 more
doaj   +1 more source

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Frontiers in Oncology, 2022
Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite extensive efforts, there is still a lack of alternatives that might improve these prospects. We uncovered that the chemotherapeutic agent temozolomide impinges on
Sweta Parik, Sweta Parik, Sweta Parik, Sweta Parik, Juan Fernández-García, Juan Fernández-García, Francesca Lodi, Francesca Lodi, Karen De Vlaminck, Karen De Vlaminck, Marleen Derweduwe, Steven De Vleeschouwer, Raf Sciot, Wietse Geens, Linqian Weng, Francesca Maria Bosisio, Francesca Maria Bosisio, Gabriele Bergers, Gabriele Bergers, Johnny Duerinck, Frederick De Smet, Diether Lambrechts, Diether Lambrechts, Jo A. Van Ginderachter, Jo A. Van Ginderachter, Sarah-Maria Fendt, Sarah-Maria Fendt   +26 more
doaj   +1 more source